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Abstract Proteomics1 is an emerging area of research of the
post-genomic era that deals with the global analysis of gene
expression using a plethora of techniques to resolve (high
resolution two-dimensional polyacrylamide gel electrophoresis,
2D PAGE), identify (peptide sequencing by Edman degradation,
mass spectrometry, Western immunoblotting, etc.), quantitate
and characterize proteins, as well as to store (comprehensive 2D
PAGE databases), communicate and interlink protein and DNA
sequence and mapping information from genome projects. Here
we review the current status as well as applications of human and
mouse proteomic 2D PAGE databases that are being system-
atically constructed for the global analysis of gene expression in
both health and disease (http://biobase.dk/cgi-bin/celis). Further-
more, we discuss the problems one faces when using powerful
proteomic technology to study heterogeneous tissue and tumor
biopsies, and emphasize the importance of building comprehen-
sive databases that contain a critical mass of information for
both known and novel proteins in normal and disease conditions.
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1. Introduction
Proteomics is an emerging area of research of the post-ge-
nomic era that deals with the global analysis of gene expres-
sion using a combination of techniques to resolve (high reso-
lution two-dimensional polyacrylamide gel electrophoresis, 2D
PAGE), identify (peptide sequencing by Edman degradation,
mass spectrometry, Western immunoblotting, etc.), quantitate
(scanners, phosphorimager, etc.) and characterize proteins, as
well as to store (comprehensive 2D PAGE databases), com-
municate and interlink protein and forthcoming DNA se-
quence and mapping information from genome projects
(http://biobase.dk/cgi-bin/celis) [1,2]. Each one of these tech-
nologies can be applied independently, although their impact
can be maximized when used in concert to the study of com-
plex biological problems.
For the last 23 years, high resolution 2D PAGE has been
the technique of choice to analyze the protein composition of
a given cell type and for monitoring changes in gene activity
through the quantitative and qualitative analysis of the thou-
sands of proteins that orchestrate various cellular functions
([3^5] and references therein). Proteins are usually the func-
tional molecules and, therefore, the most likely components to
re£ect qualitative (expression of new proteins, post-transla-
tional modi¢cations) and quantitative (up and down regula-
tion, coordinated expression) di¡erences in gene expression.
Genes may be present, they may be mutated, but they are
not necessarily transcribed. Some genes are transcribed but
not translated, and the number of mRNA copies per cell
does not necessarily re£ects the number of functional protein
molecules [6]. For these reasons focusing on the proteins has
certain advantages as compared to the mRNA based technol-
ogy.
The 2D gel technology, which was originally described by
O’Farrell [7,8] and Klose [9], separates proteins in terms of
both their isoelectric point (pI) and molecular weight. Usu-
ally, one chooses a condition of interest and lets the cell reveal
the global protein expression response, as all detected proteins
can be analyzed both qualitatively and quantitatively (relative
abundance, post-translational modi¢cations, co-regulated pro-
teins, etc.) in relation to each other. Currently, the carrier
ampholyte based 2D gel technology [7,8,10] can routinely re-
solve nearly 4000 [35S]methionine labeled polypeptides from
unfractionated cell extracts ([10], see also procedures and vid-
eos at http://biobase.dk/cgi-bin/celis). The lowest level of de-
tection for [35S]methionine labeled proteins correspond to pol-
ypeptides that are present in about 40 000 molecules per cell,
although immunoblotting in combination with enhanced
chemiluminescence (ECL) detection can reveal polypeptides
that are present in as few as 1000 molecules per cell [11].
Low abundance proteins can be visualized either by increasing
the sensitivity of the detection procedures, and/or by the anal-
ysis of subcellular fractions or partially puri¢ed protein sam-
ples. Recently, thanks to the advent of immobilized pH gra-
dients (IPGs) [12^14], which are an integral part of the
polyacrylamide matrix, one can generate more reproducible
focusing patterns to obtain enhanced resolution, as very nar-
row pH gradients of about 0.05 pH/cm can be established. In
the near future, 2D gels will continue to provide the founda-
tion for a high throughput proteomic approach, although
other alternatives are being considered [2].
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Through the years, major advances in hardware and soft-
ware development for scanning and analyzing 2D gels ([15,16]
and references therein), as well as the development of sensitive
tools for rapid protein identi¢cation (immunoblotting, Edman
degradation peptide sequencing, mass spectrometry) [17^24],
have stimulated the creation of comprehensive proteomic 2D
PAGE databases that aim at interfacing protein information
with forthcoming DNA mapping and sequence data from
genome projects, and that o¡er a global approach to the study
of gene expression both in health and disease (http://biobase.
dk/cgi-bin/celis) ([3,4,25^27] and references therein). Besides
annotating genomes, these databases are expected to address
problems that cannot be approached by DNA analysis,
namely, relative abundance of the protein product, post-trans-
lational modi¢cations, subcellular localization, turnover, in-
teraction with other proteins as well as functional aspects.
Today, using the integrated approach o¡ered by proteomic
2D PAGE databases it is possible to reveal phenotype-asso-
ciated proteins, microsequence them, search for homology
with previously identi¢ed proteins, clone the cDNAs, assign
partial protein sequences to genes for which the full DNA
sequence and the chromosome location are known, and study
the regulatory properties and function of the thousands of
protein components of organelles, pathways, and cytoskeletal
systems in health and disease [28]. Proteomics is only one of
the many technologies that are currently available for the
study of global cell regulation, and we envision that in the
near future complex biological problems will be addressed
using a plethora of technology from the realm of functional
genomics [29,30] that include genomics, high throughput pro-
teomics, cDNA arrays, phage antibody libraries as well as
transgenic animals (Fig. 1).
The purpose of this short article is to review the current
status as well as applications of human and mouse proteomic
2D PAGE databases which are being systematically con-
structed for the study of global gene expression both in health
and disease (http://biobase.dk/cgi-bin/celis). Furthermore, we
discuss the problems one faces when using powerful proteo-
mic technology to study heterogeneous tissues and tumors,
and emphasize the importance of building comprehensive da-
tabases that contain a critical mass of information for both
known and novel proteins in normal and disease conditions.
2. Aarhus proteomic databases on the Internet:
http://biobase.dk/cgi-bin/celis
2.1. The keratinocyte 2D PAGE database
The keratinocyte 2D PAGE database [31], which is being
systematically constructed using carrier ampholytes, is the
largest of its kind and currently lists 3625 cellular (2313 iso-
electric focusing, IEF; 954 non-equilibrium pH gradient elec-
trophoresis, NEPHGE) and externalized polypeptides (358,
IEF) of which 1285 have been identi¢ed using a combination
of techniques including immunoblotting [32], Edman degrada-
tion of internal peptides [33,34], and mass spectrometry [35].
It should be noted that immunoblotting was the ¢rst tool
available for the rapid identi¢cation of proteins resolved by
2D gels [36], and in a way marked the beginning of what we
now call the proteomic era.
Fig. 2 shows the synthetic master 2D PAGE image (IEF) of
non-cultured human keratinocyte proteins as depicted in the
World Wide Web (http://biobase.dk/cgi-bin/celis). Proteins
£agged with a red cross correspond to known polypeptides.
Today, mass spectrometry represents the technique of choice
for rapid protein identi¢cation, as it is fast and requires only
picomolar amounts of proteins [21,23,24]. In addition, peptide
sequencing is now possible using mass spectrometry, a fact
that will greatly speed up the identi¢cation of hitherto un-
known proteins on 2D gels as well as the cloning of genes
coding for novel proteins [19,20,22,23].
Information obtained on any given polypeptide, known or
unknown, can be easily retrieved from the database by click-
ing on the corresponding spot (in this case the spots indicated
in Fig. 2; proliferating cell nuclear antigen, PCNA, and the
unknown protein IEF SSP 8509). A ¢le listing all of the in-
formation entered for the particular protein, mostly obtained
from experiments performed in our laboratory, is displayed in
the format shown in Fig. 3 (PCNA) and Fig. 4 (IEF SSP
8509) (only a fraction of the ¢les are shown). PCNA/cyclin
[37,38] was perhaps the ¢rst interesting protein characterized
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using the 2D PAGE technology. Files for known proteinscon-
tain links to a subset of Medline (http://www.ncbi.nlm.nih.
gov/PubMed/), SwissProt (http://expasy.hcuge.ch/sprot/sprot-
top.html) and PDB (http://www.pdb.bnl.gov). Other links in-
clude OMIM (http://www.ncbi.nlm.nih.gov/Omim/), Gene-
Cards (http://bioinformatics.weizmann.ac.il/cards), UniGene
(http://www.ncbi.nlm.nih.gov/UniGene/index.html) and other
Web sites such as CySPID (cytoskeletal protein database;
http://paella.med.yale.edu/Vpanzer/cytoskdb/index.html),
metabolic pathways (compiled by KEGG; http://www.ge-
nome.ad.jp/kegg/), the cytokine explorer (http://kbot.mig.
missouri.edu:443/cytokines/explorer.html), histology images
(http://biosun.biobase.dk/Vpdi/jecelis/micrographs.html), etc.
In the future, as new databases and related Web sites become
available, it will be possible to navigate throughout various
databanks containing complementary information on nucleic
acid and protein sequences, genome mapping, diseases, pro-
tein structure, post-translational modi¢cations, antibodies and
cellular localization of the antigen, signalling pathways, his-
tology, etc.
Functions to query the databases include search by name,
protein number or keywords, molecular weight and pI, as well
as organelle or cellular component (Fig. 2, right-hand panel).
As an example, Fig. 5 shows a list of all proteins recorded in
the keratinocyte database that can be retrieved when search-
ing for proteins having Mrs between 50 and 55 kDa and pIs
between 5.0 and 5.5. The list can be extended to other data-
bases available at the site, provided one indicates so when
performing the search. By using other functions listed in
Fig. 2 it is possible to £ip (important as gels are presented
and analyzed in di¡erent orientations by various laboratories)
and enlarge the master synthetic image, as well as to retrieve a
list of known proteins and information categories available in
the database. Categories or entries are created so as to gather
information on physical, chemical, biochemical, physiological,
genetic, architectural as well as biological properties of pro-
teins. In general, entries re£ect the type of speci¢c biological
problem that is being studied using the database approach.
At present, about 80 information categories are available in
the World Wide Web version of the IEF keratinocyte data-
base, including protein name, cellular localization, proteins
di¡erentially regulated in di¡erentiated keratinocytes, proteins
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Fig. 2. Master synthetic image of human keratinocyte proteins separated by IEF 2D PAGE as depicted in the World Wide Web. Proteins
£agged with a red cross correspond to known proteins. By clicking on any spot it is possible to obtain a ¢le containing information about the
protein as well as links to other sites in the World Wide Web.
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expressed in other cell types (HeLa cells, ¢broblasts, urothelial
cells), heat shock proteins, proteins a¡ected by interleukins
(1K, 1L, 2, 3, 6, 7 and 8), proteins a¡ected by interferons
(K, L and Q), proteins di¡erentially regulated in keratinocytes
treated with various chemicals (calcium, okadaic acid, phor-
bol myristate acetate, retinoic acid, staurosporin), transforma-
tion sensitive proteins, levels in fetal human tissues, etc. Some
of these entries are also available in other databases accessible
at the Web site.
To facilitate the comparison between keratinocyte proteins
gels run with carrier ampholytes and IPGs we have provided
in the gel gallery section of our Web site IPG gel images that
can be connected directly to the master keratinocyte image, by
clicking 100 known polypeptides selected as reference. In ad-
dition, we provide protocols and videos that can be used to
reproduce the data displayed. Finally, the Web site also o¡ers
a gallery of 2D gel immunoblots that underline the value of
the 2D gel technology to determine antibody speci¢city as well
as to reveal post-translational modi¢cations. 2D blots of ker-
atinocyte proteins reacted with antibodies raised against low
abundance proteins which exhibit extensive modi¢cations
(SHC, Fig. 6A; cortactin, Fig. 6B), and developed using the
ECL procedure are shown in Fig. 6. Clearly, this technology
reveals the extent of the modi¢cation(s) and can be e¡ectively
complemented by mass spectrometry and labeling with specif-
ic radioactive precursors [39] to determine the nature of the
modi¢cation(s).
2.2. Applications of the keratinocyte database to the study of
bladder squamous cell carcinomas
So far, the keratinocyte databank has been instrumental for
the study of fresh bladder squamous cell carcinomas (SCC), as
the latter cells closely resemble keratinocytes both in morphol-
ogy and protein expression pro¢les [40^42]. Thus, by using the
information already stored in the master database, in partic-
ular information concerning di¡erentiation markers, tissue
distribution and externalized proteins, it has been possible
to identify protein markers that de¢ne the degree of di¡er-
entiation of these lesions [43] as well as a single biomarker, the
calcium binding and chemoattractant protein psoriasin [42^
45], which is expressed speci¢cally by some di¡erentiated tu-
mor cells and is externalized to the urine of SCC bearing
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Fig. 3. File for the proliferating cell nuclear antigen (PCNA). Only some of the entries available in the Internet version of the database are
shown.
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patients [42,43]. Psoriasin, alone or in combination with other
biomarkers, may be useful for the follow-up of SCC bearing
patients, in particular males, as we have previously shown that
the presence of strati¢ed squamous epithelia in the female
trigone may lead to false positives [42].
Since SCCs have a very bad prognosis, one long-term aim
of our studies is to identify premalignant lesions ^ and even-
tually protein markers that are externalized to the urine ^ that
may pinpoint individuals at risk very early during the develop-
ment of the disease. This goal is being pursued systematically
by applying proteomic technology in combination with immu-
nohistochemistry to the analysis of tumors and urothelial tis-
sue biopsies obtained from patients that have undergone re-
moval of the bladder due to invasive disease (cystectomy).
Considering that bladder cancer is a ¢eld disease [46], that
is, a large part of the bladder urothelium is at risk of devel-
oping disease, we surmised that some areas in the involved
urothelium of SCC patients may exhibit protein expression
pro¢les and immuno£uorescence staining patterns that closely
resemble those observed in the invasive tumors. These lesions,
if detected early enough in the disease process, may be crucial
in determining treatment modality.
To illustrate the approach, Fig. 7 shows immuno£uores-
cence staining of cryostat sections of an SCC tumor (Fig.
7A,C,E,G) and of the involved urothelium from the same
patient (Fig. 7B,D,F,H) reacted with antibodies against kera-
tins 19, 14, 13 and the basal antigen BG3C8 [47], respectively.
To decide which antibody to include in the immunohisto-
chemistry battery is a long process, which requires ¢rst the
analysis of the protein pro¢les of many tumors and biopsy
material exhibiting various degrees of atypia. Once major pro-
tein di¡erences are found, the next step consists in identifying
the polypeptide markers by using proteomic technology such
as microsequencing or mass spectrometry. If the proteins are
known, we usually obtain the antibodies from commercial
sources. If on the other hand they are novel, they are eluted
from the 2D gels and used to immunize rabbits and mice for
antibody production. In future, phage antibody libraries may
prove to be instrumental for the rapid production of a large
number of speci¢c antibodies for diagnostic pathology.
As depicted in Fig. 7, there is only one small region in the
abnormal urothelium of this particular section (indicated with
an arrow) that resembles the staining patterns of the tumor,
and that may be considered a putative premalignant lesion.
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Fig. 4. File for the unknown protein IEF SSP 8509. Only some of the entries available in the Internet are shown.
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Other areas of the involved urothelium show immuno£uores-
cence patterns of antigen staining that are clearly di¡erent
from those observed in the invasive tumor (indicated with
small arrows). Clearly, the heterogeneity of the tissue biopsy
is such that it would be unwise to use 2D PAGE alone to
analyze it in the absence of histological data. The latter may
also be true for approaches involving sensitive mRNA based
technology.
It should be stressed that our main project in bladder can-
cer centers around transitional cell carcinomas (TCCs), which
comprise 95% of all bladder lesions in the western hemisphere.
Our goal is to use proteomic technology to de¢ne ‘normal’
and to identify markers for the objective classi¢cation of these
lesions, as well as to reveal speci¢c proteins in the urine (tu-
mor markers, degradation products of matrix proteins) that
may identify patients at risk of developing invasive disease
[48]. To support these studies we are building large 2D
PAGE databases of tumors and urine (http://biobase.dk/cgi-
bin/celis) in an e¡ort to identify signalling pathways and com-
ponents, that are a¡ected at a given stage of tumor develop-
ment. In the long run, these studies are expected to provide a
global picture of the gene expression changes accompanying
the malignant process, and may provide with novel targets for
drug discovery.
2.3. The mouse kidney 2D PAGE database
The newborn mouse kidney (non-cultured) 2D PAGE data-
base represents the more recent addition to the set of data-
banks that we have made available through the Internet
(http://biobase.dk/cgi-bin/celis). To date, the database lists
1779 proteins (IEF), of which 223 have been identi¢ed using
2D PAGE immunoblotting, Edman degradation of internal
peptide sequences, and mass spectrometry. Information cate-
gories available so far in this database include cellular local-
ization, knockouts (see Fig. 8), as well as expression in other
mouse tissues (brain, bladder, cerebellum, ear, heart, large
intestine, liver, lung, optical nerve, skeletal muscle, skin, small
intestine, spleen, stomach, tail, thymus and tongue). To facil-
itate the comparison of protein expression pro¢les between
various tissues we have included at the Web site a gallery of
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Fig. 5. Proteins in the keratinocyte database with Mrs between 50 and 55 kDa and pIs between 5.0 and 5.5.
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reference 2D gel autoradiograms. In general, the protein ex-
pression pro¢les of tissues are qualitative rather similar (com-
pare Fig. 9A, kidney and Fig. 9B, lung), and as in the case of
human cells and tissues one would expect that a large fraction
of all expressed proteins are shared by all cell types [31].
Clearly, the database is still in its infancy but in due course
it is expected to become a major resource for the analysis of
transgenics [49^51], as one may envisage compensatory
changes in protein expression taking place as a result of the
loss or overexpression of a given gene product.
3. Perspective
A great deal of work is being devoted to the development of
high throughput technology to resolve, visualize, quantitate
and characterize proteins in an e¡ort to facilitate the study
of diseases and to expedite the process of drug discovery [2].
Today, the rapid development in high throughput proteomics
is being catalyzed in part by the pharmaceutical industry, who
sees a role for this technology in tuning up the various steps
involved in drug discovery which include target identi¢cation
and validation, drug discovery (e⁄cacy, selectivity and mode
of action), in vivo properties as well as clinical trials.
With the 2D PAGE technology available today it is rather
straightforward to reveal major protein expression changes
associated with a given disease, or with the response to a
given e¡ector (growth and di¡erentiation factors, drugs,
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Fig. 6. Proteins detected in 2D blots of whole keratinocyte proteins
reacted with antibodies against (A) SHC and (B) cortactin, and de-
tected using the ECL procedure.
Fig. 7. Immuno£uorescence pictures of formaldehyde ¢xed cryostat
sections of SCC 798-1 (A, C, E, and G) and of the involved urothe-
lium from the same patient (B, D, F and H), reacted with antibod-
ies against keratin 19 (A, B), keratin 14 (C, D), keratin 13 (E, F)
and the basal antigen BG3C8 (G, H). From Celis et al. [52].
Fig. 8. IEF 2D gels of [35S]methionine labeled externalized proteins from primary adult kidney cells (overnight culture) from (A) normal and
(B) L2 microglobulin knockout mice. The arrowhead indicates the position of an acidic variant of L2 microglobulin. From Celis et al. [10].
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etc.), but the question still remains which of these changes are
primarily associated with the disease or the e¡ector. Thus,
having at hand additional information to narrow the possibil-
ities seems crucial at this time, and it is in this context that
comprehensive proteomic 2D PAGE databases containing a
critical mass of information may prove to be invaluable in
rapidly sorting out the putative targets of interest. Making a
2D PAGE database of a cell line is not a problem as the
cultures are rather homogeneous, but building databanks of
normal tissues and disease biopsy material is a di¡erent prop-
osition as the heterogeneity of the samples requires ¢rst hand
knowledge of the biology of the tissue in question, as well as
probes (antibodies) to identify the various cell types that con-
tribute to the overall protein expression pattern. We believe
that in the near future phage antibody libraries ([53], and
references therein) may become instrumental for the rapid
generation of speci¢c antibodies against proteins of interest
revealed by the 2D PAGE technology, and in combination,
they may o¡er a unique platform for building up the ¢eld of
molecular pathology.
Clearly, there are many limitations associated with building
up large 2D PAGE databases that go beyond the heterogene-
ity of the samples. These include the detection of very low
abundance polypeptides, the resolution of very basic and
high molecular weight proteins, as well as the lack of satis-
factory quantitation procedures for the analysis of all the
proteins resolved in the gels. Some of these shortcomings
are being addressed by developing larger and better gel sepa-
ration systems, more sensitive dyes for protein detection, by
the analysis of fractionated protein samples and subcellular
fractions, as well as by the development of better software for
spot detection and quantitation. In addition, there are e¡orts
being devoted to standardizing the gel technology in general,
so that information gathered in any given laboratory can be
readily used by others in the scienti¢c community.
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